What You'll Learn
Table of Contents
Three Receptors Instead Of One
Semaglutide acts on one receptor: GLP-1. Tirzepatide acts on two, adding GIP. Retatrutide acts on three — GIP, GLP-1 and, the addition that makes it different, glucagon.
The glucagon arm is the interesting part. Glucagon receptor agonism increases energy expenditure, so where the existing drugs work almost entirely by reducing how much you eat, retatrutide is also pushing on the other side of the equation. That is the mechanistic argument for why its numbers are larger.
It is made by Eli Lilly, the same company as tirzepatide, and it is in phase 3 development. It has no approval anywhere in the world.
If the drug class itself is unfamiliar, start here, and four names, two drugs covers what is actually licensed today.
What The Phase 2 Trial Found
A phase 2, double-blind, randomised, placebo-controlled trial in 338 adults with obesity, or overweight plus a weight-related condition, run for 48 weeks across several doses.
Mean weight change at 48 weeks:
- 1 mg: −8.7%
- 4 mg: −17.1%
- 8 mg: −22.8%
- 12 mg: −24.2%
- Placebo: −2.1%
And the distribution, which matters more than the mean and is the thing the GLP-1 response spread makes clear. At 12 mg: 100% of participants reached 5% loss or more, 93% reached 10%, 83% reached 15%. On placebo: 27%, 9% and 2%.
A hundred per cent reaching 5% is not a figure this field produces often. For context, in STEP-1 semaglutide reached 5% in 86.4% and 15% in 50.5%.
This is genuine, well-designed, published evidence. Whatever else follows, that part is not in doubt.
338 adults, 48 weeks. At 12 mg: mean weight change −24.2% against −2.1% on placebo, with 100%, 93% and 83% of participants reaching 5%, 10% and 15% loss respectively. Gastrointestinal adverse events were dose-related and mostly mild to moderate.
PMID: 37366315 ↗The Body Composition Data, Read Carefully
A separate substudy scanned participants with DXA at week 36. Fat mass fell 26.1% on 8 mg and 23.2% on 12 mg, against 4.5% on placebo and 2.6% on dulaglutide. As a fat-loss result that is emphatic.
The paper's own interpretation is where this needs care. It states that the proportion of lean mass loss to weight loss was similar to other obesity treatments, and offers that as reassurance that a greater proportion of lean mass is not lost despite the larger total.
That is accurate. It is also not the same as saying you lose less lean tissue.
Hold the proportion constant and increase the total, and the absolute quantity goes up with it. If roughly a quarter of lost weight is lean mass, a 24% total loss removes considerably more lean tissue than a 15% loss at the same ratio. “The same fraction of a much bigger number” is a different fact from “less lean mass”, and only the first is what the data shows.
Which puts retatrutide in the same place as every other drug in this class, only more so: the lean mass question gets bigger as the weight loss gets bigger, and protein and resistance training are the levers that change the ratio.
One more thing worth knowing about that substudy before leaning on it: 189 participants were enrolled, 155 had a baseline scan, and 103 completed treatment with both scans. It was funded by the manufacturer, which is normal at this stage and worth stating plainly.
Bottom line: A proportion and an absolute amount are different quantities, and press coverage of body-composition results routinely swaps one for the other. When you read that lean mass loss was “similar”, check whether the claim is about the fraction or the kilograms.
The Signal Almost Nobody Mentions
In the same phase 2 trial: dose-dependent increases in heart rate, peaking at 24 weeks and declining thereafter.
That is in the published abstract, and it is largely absent from the enthusiastic coverage. It is not a scandal — it is a known consequence of glucagon receptor agonism, it was measured, it was reported, and it fell back after week 24. It is exactly the sort of finding a phase 3 programme is designed to characterise properly.
It is also exactly the sort of finding that matters when a compound is being bought from a website and injected without monitoring by anyone.
Gastrointestinal adverse events were the most common overall, dose-related, mostly mild to moderate, and partly reduced by starting at a lower dose — the same pattern as the approved drugs in this class.
Why You Cannot Lawfully Buy It
Retatrutide is not approved in the United States, the United Kingdom, the European Union or anywhere else. It is an investigational compound in phase 3.
The FDA's position is unusually direct, and it names this compound specifically. Retatrutide:
- Cannot be used in compounding under federal law.
- Is not a component of any FDA-approved drug.
- Has not been found safe and effective for any condition.
The agency has issued warnings to telehealth companies marketing unapproved drugs including retatrutide directly to consumers, to active pharmaceutical ingredient distributors selling it to compounders, and to outsourcing facilities repackaging it.
So anything offering it for sale is, by definition, operating outside that framework. Which raises the question you cannot answer from the trial data: the NEJM result describes pharmaceutical-grade retatrutide, manufactured under controls, at a known dose, in monitored participants. It tells you nothing about what is in a vial bought online — and the FDA's parallel concerns about peptide impurities and active-ingredient characterisation apply here as much as they do to BPC-157.
Important: A published trial result is evidence about the molecule the trial used. It is not evidence about a product sold under the same name by someone who did not run the trial.
What A Phase 2 Result Is Not
Phase 2 answers whether a compound does the thing, and roughly at what dose. It is not the end of the process, and the gap between phase 2 and approval is where a fair number of promising drugs stop.
Still open:
- Long-term safety. 48 weeks in 338 people is not the exposure needed to detect uncommon harms. SELECT, by contrast, followed 17,604 people for a mean of 39.8 months — and that is what a hard outcome trial looks like.
- Cardiovascular outcomes. Weight loss is a surrogate. Whether retatrutide reduces heart attacks and strokes is not known.
- What happens on stopping. Not addressed here, and the discontinuation data for this class is not encouraging.
- The heart rate finding, characterised properly.
None of this is a reason to dismiss the compound. Phase 3 exists precisely to answer these, and on the phase 2 numbers retatrutide looks like the most effective weight-loss agent yet trialled.
It is a reason not to treat a phase 2 result as a licence to obtain it from a website. The people in that trial had a known product, a known dose and a clinician watching their heart rate. Someone buying it online has none of the three, and the trial they are citing is the reason they think they do not need them.
